Category: united states

Case closed? Fired Pfizer researcher slated for seven retractions

Pfizer has discovered two additional papers that merit retraction from the lab of a former employee. One of the papers, published in Clinical Cancer Research, was retracted earlier this month.

Last year, Pfizer requested retractions of five papers from the lab of breast cancer researcher Min-Jean Yin, who was fired after an investigation revealed image duplication. The papers were first questioned on PubPeer. By April 2017, all five papers had been retracted.

After the initial probe, the pharmaceutical giant conducted a follow-up review of papers originating from Yin’s lab (which Leonid Schneider posted about on May 23). A spokesperson for the company told us that the review revealed two more articles that merited retraction “in light of data integrity issues relating to the figures therein.” The 2013 paper in Clinical Cancer Research was retracted earlier this month at Pfizer’s request. On May 1, 2017, Pfizer asked PLOS ONE to retract a 2013 paper. Continue reading Case closed? Fired Pfizer researcher slated for seven retractions

Publisher flags paper on same-sex parenting after neo-Nazi group cites it

A publisher has issued an expression of concern (EoC) about a study that claimed children with same-sex parents were at greater risk of depression and abuse, after posters using statistics from the paper to support a homophobic message appeared in Australia and the US.

On Aug. 21, several news websites reported that these posters were appearing in Melbourne, Australia, citing claims from a 2016 paper published in Depression Research and Treatment, which said that children with same-sex parents are more at risk for depression, abuse, and obesity than children with opposite-sex parents. The poster had also appeared previously in Minneapolis and has been traced to a neo-Nazi group, as reported by HuffPost Australia. Australia is preparing for a national, non-binding, mail-in vote on whether to provide marriage equality for same-sex couples.

The EoC mechanism, which was chosen by the journal’s publisher, Hindawi, is an unusual choice here. The paper’s author, D. Paul Sullins, a sociology professor at The Catholic University of America and the paper’s author, told Retraction Watch that Hindawi contacted him Aug. 21 about the decision. Initially, he told us he didn’t have any “particular objection to it,” but later told us he changed his mind after he read more about COPE’s guidelines for EoCs: Continue reading Publisher flags paper on same-sex parenting after neo-Nazi group cites it

Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Jodi Whitaker, via University of Arizona

[This post, which at 1200 UTC 8/25/17 originally reported on the then-upcoming vote, has been updated at 1800 UTC 8/25/17 to include the results of the vote.]

A researcher who co-authored a paper about video games that was retracted earlier this year has had her PhD from The Ohio State University revoked.

As WOSU reported this afternoon, the vote today of the university’s Board of Trustees was unanimous. The scheduled vote on whether to revoke Jodi Whitaker’s degree was first reported yesterday by The Columbus Dispatch.

While a graduate student at Ohio State, Whitaker was co-author of a paper that claimed to find that first-person shooter video games improved marksmanship. As we’ve reported, the paper, published online in 2012, was retracted earlier this year, two years after a university committee was alerted to irregularities in the data by two outside researchers.

The controversy over the paper became heated at times. Continue reading Updated: Ohio State revokes PhD of co-author of now-retracted paper on shooter video games

Former MD Anderson researcher objects to retraction of his paper

A cell biology journal has retracted a 2016 paper after an investigation revealed that the corresponding author failed to include two co-authors and acknowledge the funding source.

According to the retraction notice, the Journal of Cellular Physiology retracted the paper after the University of Texas, MD Anderson Cancer Center found that last author Jin Wang had omitted two researchers from the list of authors, and had also failed to acknowledge funding from the U.S. National Institutes of Health (NIH).

But Wang tells a different story. Continue reading Former MD Anderson researcher objects to retraction of his paper

Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

A group of researchers have retracted their 2016 case report about a rare dermatologic disorder in the wake of disputes about authorship and institutional approval.

The paper describes a young boy with Job’s Syndrome, in which patients experience painful, itchy and frequently disfiguring skin lesions, along with a constellation of other possible symptoms. The condition is extremely rare, occurring in less than one in 1 million births.

This isn’t the first time a journal has retracted a case study after another group of authors claimed ownership of the case. Earlier this year, we covered a retraction from a neuro-ophthalmology journal after the doctors who treated a patient suffering from a gruesome eye trauma took issue with the fact that radiologists had already published their diagnostic images as a case study.

According to the notice for this latest retraction:

Continue reading Hey, that’s my case study: Another retraction after doctors claim rights to case write-up

Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the FDA via a lawsuit shed light on the attempt — and show how tricky it can be to correct the official record.

The controversy surrounds the approval of eteplirsen, a drug approved last September to treat Duchenne Muscular Dystrophy, a rare but invariably fatal disease that strikes (mostly) young boys. Eteplirsen was approved over the objections of the FDA team that reviewed the drug, which determined that there was insufficient evidence to approve the drug.

But the controversy didn’t end within the walls of the FDA complex. Ellis Unger, who led the review team, believed that one of the principal studies of the drug, published in the Annals of Neurology, was “misleading” because it was based on “unreliable data.” So in early November, Unger, joined by the then-head of the FDA, Robert Califf, took the extremely rare move of writing to the editor of the journal to “urge that the paper be corrected or retracted….”

According to the documents, the authors of the Annals article did, in fact, agree to correct the article.

On November 9, 2016, Clifford Saper, Annals‘ editor in chief, wrote to Califf and Unger:

Continue reading Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

In June, Gene Emery, a journalist for Reuters Health, was assigned to write a story about an upcoming paper in the Journal of the American College of Cardiology, set to come off embargo and be released to the public in a few days. Pretty quickly, he noticed something seemed off.

Emery saw that the data presented in the tables of the paper — about awareness of the problem of heart disease among women and their doctors — didn’t seem to match the authors’ conclusions. For instance, on a scale of 1 to 5 rating preparedness to assess female patients’ risk (with 5 being the most prepared), 64% of doctors answered 4 or 5; but the paper said “only a minority” of doctors felt well-prepared (findings echoed in an accompanying press release). On Monday June 19, four days before the paper was set to publish, Emery told the corresponding author — C. Noel Bairey Merz, Medical Director of the Women’s Heart Center at Cedars-Sinai in Los Angeles — about the discrepancy; she told him to rely on the data in the table.

But the more Emery and his editors looked, the more problems they found with the paper. They alerted the journal hours before it was set to publish, hoping that was enough to halt the process. It wasn’t.

Continue reading Journal knew about problems in a high-profile study before it came out — and did nothing for over a month

Recent finding of misconduct by federal U.S. agency sparks debate

Nasser Chegini

In 2011, the University of Florida assembled a misconduct report about one of its ob-gyn researchers, identifying falsified data in a 2010 paper. But when an investigator at the U.S. Office of Research Integrity reviewed the report, something didn’t feel right.

“I reviewed the data, and I thought [UF] didn’t do their due diligence,” said Kristen Grace, then an ORI investigator, now heading up the compliance department of the Office of Clinical Research at the University of Pennsylvania. “Because the extent of the the falsification was so great.”

So the ORI asked the UF to re-open its investigation, expanding it to include previous years of work by Nasser Chegini, now retired. The institution also hired a new director of research compliance, who oversaw the second investigation. That report, completed in October 2013, was significantly more extensive — it documented intentional falsifications or fabrications in nine papers published between 2003-2008. (Through a public records request, we obtained a copy of this second report, which you can read in full here.) But last month, the ORI issued a finding of misconduct against Chegini that focused on only one paper; the agency said it chose to take a “targeted approach,” since eight of the nine papers had already been retracted.  

The move has prompted a debate — while some argue it’s a pragmatic use of ORI’s limited resources, others (including Grace) are concerned:

Continue reading Recent finding of misconduct by federal U.S. agency sparks debate

What should journals do when peer reviewers do not disclose potential conflicts?

Peer reviewers, like authors, are supposed to declare any potential conflicts of interest. But what happens when they don’t?

Take this case: In a court transcript from Feb. 23, 2017, Bryan Hardin testified that he was a peer reviewer on a 2016 paper in Critical Reviews in Toxicology, which found that asbestos does not increase the risk of cancer. In the deposition, Hardin—who works at the consulting firm Veritox—also said that he has testified in asbestos litigation on behalf of automakers, such as Ford, General Motors, and Chrysler, but said he had not disclosed these relationships to the journal.

Last year, the first author of the 2016 review withdrew a paper from another journal (by the same publisher) which concluded asbestos roofing products are safe, following several criticisms — including not disclosing the approving editor’s ties to the asbestos industry. In this latest case, the journal told us it believes the review process for the paper was up to snuff, but two outside experts we consulted said they believed Hardin’s relationships — and failure to disclose them — should give the journal pause.

We obtained a copy of the transcript from Christian Hartley, who was representing a man suing a mining company because the man developed cancer after being exposed to asbestos at work. When Hartley asked Hardin whether he had told the journal about testifying for companies involved in asbestos litigation, Hardin responded:

Continue reading What should journals do when peer reviewers do not disclose potential conflicts?

Researcher who shot dean after being fired for misconduct sentenced to 28 years in prison

Hengjun Chao. Credit: Westchester County DA

A former researcher at Mount Sinai’s medical school has been sentenced to 28 years in prison for shooting the dean that fired him.

On the morning of Aug. 29, 2016, Chao, 50, attacked Dennis Charney, dean of the Icahn School of Medicine at Mount Sinai, with a shotgun outside a deli in suburban New York. In 2010, Charney fired Chao for scientific misconduct. Charney survived the shot, but was hospitalized for five days.

As reported by the Chappaqua-Mount Kisco Patch yesterday, Judge Barry Warhit sentenced Hengjun Chao to 23 years, each, for attempted murder and assault, to be served concurrently; the maximum sentence for the attempted murder charge that Chao faced was 25 years. The judge also sentenced Chao to the maximum for criminal use of a firearm — five years — which will be served consecutively, bringing the total to 28 years.

In June, a New York jury found him guilty of attempted murder and the two other felony charges.

Stewart Orden, Chao’s defense attorney, told Retraction Watch he was “shocked at the sentence:” Continue reading Researcher who shot dean after being fired for misconduct sentenced to 28 years in prison